Avadel Pharma (AVDL) Tops Q3 EPS by 5c

Avadel Pharma (NASDAQ: AVDL) reported Q3 EPS of ($0.03), $0.05 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $50.03 million versus the consensus estimate of $48.44 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.

You May Also Be Interested In

• Lyntris opens at $15.50, below IPO price of $17.50
• North Korea dismisses US military drill cuts, denies Trump talks
• Moderna short sellers face $4.8 billion loss amid record stock jump